Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FLOT chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival. Patients were treated with neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. For the secondary endpoint of overall survival, a strong trend was observed in favor of the Imfinzi -based regimen at this interim analysis. The trial will continue to follow OS, which will be formally assessed at the final analysis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS
- Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug
- Nvidia-Backed CoreWeave Buys Weights & Biases as It Preps for IPO
- AstraZeneca says Imfinzi-based perioperative regimen recommended for EU approval
- AstraZeneca’s Growth Potential Highlighted by Positive Risk-Reward Scenario and Strategic Drug Portfolio